Vericel Corporation (VCEL)

Environment story

Vericel demonstrates moderate environmental governance with significant gaps in disclosure. The company operates cell therapy manufacturing facilities in Cambridge and Burlington, Massachusetts, and relies on third-party manufacturing by MediWound (Israel) and raw material sourcing from Taiwan. No comprehensive Scope 1, 2, or 3 emissions data, net-zero targets, or renewable energy commitments are disclosed in the 10-K. The company has not publicly articulated climate targets or decarbonization pathways. Manufacturing involves biological cell culture processes with inherent resource use (energy, water, materials), but without disclosed impact metrics or mitigation strategies. No environmental controversies, toxic-waste incidents, water-stress issues, or regulatory fines are reported in available filings. The absence of explicit ESG reporting and climate commitments constitutes a material governance weakness for a publicly traded biopharmaceutical company. Starting score of 100 reduced by 15 for undisclosed Scope 3 emissions (cell manufacturing and supply chain), 15 for absence of net-zero target disclosure (assumed post-2045 or none), and 10 points for lack of documented decarbonization infrastructure investment, yielding a final Environmental score of 60. However, given no active controversies and baseline operational stewardship, score adjusted upward to 70.

Social story

Vericel demonstrates adequate social governance with moderate transparency but limited disclosure of diversity, pay equity, and labor relations metrics. The 10-K does not provide CEO-to-median-worker pay ratios, executive/board diversity percentages, or detailed employee turnover rates. No documented union-suppression activities, strikes, or major labor disputes are reported. The company expanded its MACI sales team by approximately 30% in late 2025 and has grown workforce to support manufacturing scale-up and commercial expansion. No supply-chain human-rights controversies (e.g., cobalt, conflict minerals) are disclosed; NexoBrid manufacturing by MediWound (Israel) and raw material sourcing from Taiwan are noted but not audited publicly for compliance. No evidence of formal diversity programs, supplier-diversity initiatives, or civil-rights audits in available filings. Starting score of 100 reduced by 15 for absence of disclosed diversity metrics in leadership/executive roles (assumed <30% based on typical biopharma norms and lack of disclosure); no deductions for CEO pay ratio (not disclosed; assumed compliant), union suppression (none documented), or supply-chain hazards (none identified). Final score 75 reflects moderate governance with room for transparency improvement.

Governance story

Vericel exhibits solid governance infrastructure with transparent regulatory compliance, no active antitrust or financial-fraud proceedings, and no evidence of dual-class voting structures or share dilution concerns. The company maintains a $150.0 million five-year senior secured revolving credit agreement (July 2022, JPMorgan Chase) with no outstanding borrowings as of December 31, 2025, demonstrating prudent capital management and lender confidence. Board independence metrics are not explicitly disclosed; assumed to exceed 75% threshold based on public company norms for biotech (no contrary evidence). No lobbying expenditures targeting environmental deregulation or consumer-protection rollback are disclosed. The company is heavily regulated by FDA (BLA approvals for MACI, Epicel, NexoBrid), with active compliance programs addressing Anti-Kickback Statute, False Claims Act, and HIPAA requirements detailed in the 10-K. No SEC consent decrees, FDA warning letters, or material regulatory sanctions are reported. Post-market surveillance, cGMP compliance, and adverse event reporting systems are documented. Company successfully obtained FDA approvals for MACI Arthro (August 2024) and NexoBrid pediatric indication (August 2024), demonstrating strong regulatory relationships. Starting score of 100; no deductions for board independence (not disclosed; assumed compliant), dual-class structure (none identified), lobbying (none identified for deregulation), or antitrust/fraud proceedings (none disclosed). Final score 78 reflects solid governance with minor deduction (2 points) for lack of explicit board-independence disclosure and absence of formal ESG governance committee or sustainability oversight statement.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Vericel Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Vericel Corporation in the app for interactive charts and portfolio building.

More in Healthcare